Double-Team attack: new CAR-T therapy targets two cancer markers to outsmart relapse

NCT ID NCT07523555

Recruiting now Disease control Sponsor: Beijing Biotech Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of CAR-T cell therapy that targets two different markers on cancer cells at once, aiming to prevent the cancer from escaping treatment. It is for adults with several types of blood cancers that have come back or not responded to standard treatments. Participants receive an infusion of their own immune cells that have been engineered to attack their specific cancer based on biomarker testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dual-target CAR-T cells (CD19/CD22, CD19/CD20, BCMA/CD19, BCMA/CD38, BCMA/GPRC5D, CD33/CD123, CD33/CLL1, or CD5/CD7)
What this could lead to: If successful, this could provide a more effective treatment option for people with hard-to-treat blood cancers by reducing the chance of cancer cells escaping the therapy.
What could go wrong: This is an early-phase trial (phase 1/2) with a small number of participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BPDCN; RELAPSED/REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia B-cell neoplasm Blastic Plasmacytoid Dendritic Cell Neoplasm Burkitt lymphoma hematopoietic and lymphoid system neoplasm mature T-cell and NK-cell non-Hodgkin lymphoma plasma cell leukemia plasma cell myeloma Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Recurrence T-lymphoblastic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BPDCN; RELAPSED/REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PERIPHERAL T-CELL LYMPHOMA RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA, HIGH-RISK MYELODYSPLASTIC NEOPLASM RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA OR CLL/SLL RELAPSED/REFRACTORY MULTIPLE MYELOMA OR PLASMA CELL LEUKEMIA T LYMPHOBLASTIC LYMPHOMA

Contacts and locations

Locations

Peking University Shenzhen Hospital
RECRUITING

Shenzhen, Guangdong, 518036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.